Cowen & Co. Thinks Agios Pharma’s Stock is Going to Recover


In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Agios Pharma (AGIO). The company’s shares opened today at $50.66, close to its 52-week low of $41.63.

According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 2.0% and a 41.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

Agios Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $76.67.

See today’s analyst top recommended stocks >>

Based on Agios Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $93.08 million. In comparison, last year the company had a GAAP net loss of $90.83 million.

Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGIO in relation to earlier this year. Earlier this month, Scott Biller, the CSO of AGIO bought 7,218 shares for a total of $16,818.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts